Natixis Advisors LLC bought a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 28,482 shares of the biopharmaceutical company's stock, valued at approximately $857,000.
A number of other hedge funds have also added to or reduced their stakes in TGTX. Blue Trust Inc. grew its position in shares of TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock worth $57,000 after buying an additional 371 shares during the period. Smartleaf Asset Management LLC boosted its stake in TG Therapeutics by 512.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock worth $60,000 after acquiring an additional 1,594 shares in the last quarter. Jones Financial Companies Lllp increased its stake in TG Therapeutics by 460.7% in the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock valued at $64,000 after purchasing an additional 1,737 shares in the last quarter. Synergy Asset Management LLC bought a new stake in TG Therapeutics in the fourth quarter valued at $75,000. Finally, GAMMA Investing LLC raised its holdings in shares of TG Therapeutics by 562.4% during the fourth quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company's stock valued at $77,000 after purchasing an additional 2,171 shares during the period. 58.58% of the stock is currently owned by institutional investors.
Insider Activity at TG Therapeutics
In other news, CFO Sean A. Power sold 11,337 shares of the firm's stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $30.29, for a total value of $343,397.73. Following the completion of the transaction, the chief financial officer now directly owns 670,632 shares in the company, valued at approximately $20,313,443.28. This trade represents a 1.66 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.50% of the stock is currently owned by corporate insiders.
TG Therapeutics Stock Performance
Shares of TGTX traded down $0.34 during trading hours on Friday, hitting $39.86. The company's stock had a trading volume of 1,642,962 shares, compared to its average volume of 3,069,404. The company has a market cap of $6.26 billion, a price-to-earnings ratio of -398.56 and a beta of 2.30. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The business has a 50 day simple moving average of $34.37 and a two-hundred day simple moving average of $30.39. TG Therapeutics, Inc. has a 52-week low of $12.93 and a 52-week high of $43.32.
TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.08 by $0.07. The business had revenue of $108.19 million for the quarter, compared to analysts' expectations of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. On average, equities analysts expect that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of equities analysts have recently issued reports on the stock. StockNews.com raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. HC Wainwright reissued a "buy" rating and issued a $55.00 price objective on shares of TG Therapeutics in a research note on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, TG Therapeutics has an average rating of "Moderate Buy" and an average price target of $40.67.
Check Out Our Latest Analysis on TGTX
TG Therapeutics Company Profile
(
Free Report)
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Further Reading
Before you consider TG Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TG Therapeutics wasn't on the list.
While TG Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
